Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482341 | PMC |
| http://dx.doi.org/10.1136/bmj.332.7556.1494 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Twenty-Five Years of Evolution and Hurdles in Electronic Health Records and Interoperability in Medical Research: Comprehensive Review.
J Med Internet Res
January 2025
Chronic Disease Epidemiology, Population and Public Health, Pennington Biomedical Research Center, Baton Rouge, LA, United States.
Background: Electronic health records (EHRs) facilitate the accessibility and sharing of patient data among various health care providers, contributing to more coordinated and efficient care.
Objective: This study aimed to summarize the evolution of secondary use of EHRs and their interoperability in medical research over the past 25 years.
Methods: We conducted an extensive literature search in the PubMed, Scopus, and Web of Science databases using the keywords Electronic health record and Electronic medical record in the title or abstract and Medical research in all fields from 2000 to 2024.
Effects of oral intake, symptom severity, and sex difference on cancer patient prognosis.
Support Care Cancer
January 2025
Department of Psychosomatic Internal Medicine, Nihon University Itabashi Hospital, Tokyo, Japan.
Purpose: For cancer patients, prognostication by physicians constitutes a fundamental basis of decision-making to manage the cancer journey, especially with advanced stages of cancer. Various tools such as the palliative prognostic index (PPI) have been established to estimate patient survival. Such reliable and widely applied tools unfortunately provide unexpected results of prognosis predictions in some cases.
View Article and Find Full Text PDFBackground: Recent developments in blood biomarkers (BBM) have shown promising results in diagnosing amyloid pathology in Alzheimer's Disease (AD). However, information on how these BBMs can best be used in clinical settings to optimise clinical decision-making and long-term health outcomes for individuals with AD is still lacking. We aim to assess the potential clinical and economic value of BBM in AD diagnosis within the context of disease-modifying treatment (DMT).
View Article and Find Full Text PDFBackground: Qualitative patient interviews are increasingly conducted alongside clinical trials; interviews administered early in drug development can yield insight into the patient journey. Examination among patient subgroups may identify factors that influence the patient experience, including trial participation. As part of the INTERCEPT-AD phase 1 study evaluating the safety and tolerability of the Aβ oligomer-targeting monoclonal antibody ACU193, we conducted semi-structured qualitative interviews among a subset of participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) and their study partners to obtain feedback on their trial experience and the decision-making process preceding trial enrollment; results were compared between study participant genders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!